Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 9:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: HP MRI Clear all
Completed Early Phase 1 Interventional

Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

NCT05851378
View directory record Official record
Conditions
Adult Gliomas, Mixed
Interventions
Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG), Magnetic Resonance Image (MRI)
Drug · Procedure
Lead sponsor
Robert Bok, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 16, 2026, 9:30 AM EDT
Active, not recruiting Phase 2 Interventional

Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors

NCT04258462
View directory record Official record
Conditions
Benign Kidney Neoplasm, Kidney Neoplasm, Renal Cell Cancer
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Hyperpolarized 13C,15N2-urea
Drug · Procedure
Lead sponsor
Zhen Wang, MD
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 16, 2026, 9:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway

NCT03480594
View directory record Official record
Conditions
Fatty Liver
Interventions
MRI Tracer
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 16, 2026, 9:30 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI

NCT04941573
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Hyperpolarized 129-Xenon (MagniXene) MRI of the lung
Combination Product
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 16, 2026, 9:30 AM EDT
Suspended Phase 1 Interventional

Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection

NCT05873699
View directory record Official record
Conditions
Pancreatic Cyst
Interventions
Hyperpolarized 13-C-pyruvate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 16, 2026, 9:30 AM EDT
Completed Phase 2 Interventional Results available

Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI

NCT03367312
View directory record Official record
Conditions
Pulmonary Vascular Disease
Interventions
Hyperpolarized 129Xenon gas
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 16, 2026, 9:30 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI)

NCT03759704
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
Hyperpolarized 13CPyruvate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 16, 2026, 9:30 AM EDT
Completed Phase 2 Interventional Results available

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT05730712
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Enzalutamide, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 16, 2026, 9:30 AM EDT
Recruiting No phase listed Observational

Hyperpolarized 129Xe MRI Lung Health Cohort

NCT05766384
View directory record Official record
Conditions
Healthy
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
25 Years to 35 Years
Enrollment
260 participants
Timeline
2023 – 2027
U.S. locations
6
States / cities
Chicago, Illinois • Iowa City, Iowa • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 16, 2026, 9:30 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

NCT07510607
View directory record Official record
Conditions
Multiple Sclerosis, RRMS, Relapsing Remitting MS
Interventions
HP 13C pyruvate injection, MRI Scanner
Drug · Device
Lead sponsor
Ari Green
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 16, 2026, 9:30 AM EDT
Active, not recruiting Early Phase 1 Interventional

Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer

NCT05851365
View directory record Official record
Conditions
Prostate Cancer, Localized Prostate Carcinoma
Interventions
Hyperpolarized Bicarbonate (13C), Magnetic Resonance imaging
Drug · Procedure
Lead sponsor
Robert Flavell, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 16, 2026, 9:30 AM EDT
Recruiting Phase 2 Interventional

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

NCT05746208
View directory record Official record
Conditions
Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
Interventions
Lenvatinib, Pembrolizumab, Hyperpolarized 13C-Pyruvate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 16, 2026, 9:30 AM EDT
Recruiting Phase 2 Interventional

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

NCT06391034
View directory record Official record
Conditions
Prostate Cancer
Interventions
hyperpolarized pyruvate +/-urea (13C/15N), Non-investigational External beam radiotherapy (EBRT), Radiotherapy (RT), Multi-parametric magnetic resonance imaging (mpMRI), Non-interventional hormone therapy, Prostate Biopsy
Drug · Radiation · Procedure + 1 more
Lead sponsor
Robert Bok, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 16, 2026, 9:30 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

129Xe MRI in Pediatric Population With BPD

NCT04035629
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
MagniXene, hyperpolarized 129Xe MRI
Combination Product
Lead sponsor
Xemed LLC
Industry
Eligibility
Up to 1 Year
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 16, 2026, 9:30 AM EDT
Suspended Phase 2 Interventional

Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy

NCT03952598
View directory record Official record
Conditions
Glioma, Gliomas, High Grade Glioma, Malignant Glioma, Low Grade Glioma
Interventions
HP 13C Pyruvate, 3T MRI scanner
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 16, 2026, 9:30 AM EDT
Active, not recruiting Phase 2 Interventional

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

NCT06384222
View directory record Official record
Conditions
High Risk Prostate Carcinoma, Prostate Cancer
Interventions
Abiraterone acetate, Prednisone, Hyperpolarized [1-13C] pyruvate (HP 13C), Magnetic Resonance Imaging (MRI), Non-investigational radical prostatectomy (RP), Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)
Drug · Procedure
Lead sponsor
Ivan de Kouchkovsky, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 16, 2026, 9:30 AM EDT
Completed No phase listed Observational

Post-surgical Aortic Hemodynamics After Aortic Valve Replacement

NCT03347851
View directory record Official record
Conditions
Valve Heart Disease
Interventions
MRI, Transthoracic echocardiography exam
Other
Lead sponsor
CryoLife, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Sep 16, 2026, 9:30 AM EDT
Recruiting Phase 1Phase 2 Interventional

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

NCT05599048
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Hyperpolarized 13C-Pyruvate, Magnetic Resonance Imaging (MRI), 13C,15N-Urea
Drug · Procedure
Lead sponsor
Robert Bok, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 16, 2026, 9:30 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders

NCT00846573
View directory record Official record
Conditions
COPD, Cystic Fibrosis, Asthma, Healthy
Interventions
Hyperpolarized Helium-3
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
5 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Sep 16, 2026, 9:30 AM EDT
Completed Phase 2 Interventional Results available

Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging

NCT03078192
View directory record Official record
Conditions
Pulmonary Vascular Disease
Interventions
GE-141, Hyperpolarized 129Xenon gas, MRI
Drug · Device
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 16, 2026, 9:30 AM EDT
Completed Phase 1 Interventional

Hyperpolarized 129Xe MRI of Survivors of COVID-19

NCT04659707
View directory record Official record
Conditions
Covid19
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 16, 2026, 9:30 AM EDT
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers

Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate

NCT03502967
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Hyperpolarized [1-13C] Pyruvate, Hyperpolarized [2-13C] Pyruvate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 16, 2026, 9:30 AM EDT
Completed Phase 1 Interventional

Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors

NCT02947373
View directory record Official record
Conditions
Pediatric Brain Tumors
Interventions
Hyperpolarized Pyruvate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 16, 2026, 9:30 AM EDT
Completed Not applicable Interventional

Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma

NCT02359097
View directory record Official record
Conditions
Glioblastoma
Interventions
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadoteridol, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Columbus, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 16, 2026, 9:30 AM EDT